Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Completed 3Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 2Breast 2Gynecologic 1Dermatologic 1

Conditions

Breast Neoplasms 2Peritoneal Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × soluble LAG-3 protein, human × Clear all
NCT03252938 2026-02-19

INSIGHT

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 1 Active not recruiting
83 enrolled
GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT04252768 2023-03-22

AIPAC-002

Immutep S.A.S.

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT02676869 2019-12-18

TACTI-mel

Immutep Australia Pty. Ltd.

Phase 1 Completed
24 enrolled
Dermatologic

Melanoma

NCT00349934 2010-01-07

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Immutep S.A.S.

Phase 1 Completed
33 enrolled
Breast

Breast Neoplasms

NCT00351949 2010-01-07

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

Immutep S.A.S.

Phase 1 Completed
24 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡